Cargando…
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress
Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance. The activation of Akt by sorafenib is thought to be responsible for this resistance. Bufalin is the major active ingred...
Autores principales: | Zhai, Bo, Hu, Fengli, Yan, Haijiang, Zhao, Dali, Jin, Xin, Fang, Taishi, Pan, Shangha, Sun, Xueying, Xu, Lishan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575108/ https://www.ncbi.nlm.nih.gov/pubmed/26381511 http://dx.doi.org/10.1371/journal.pone.0138485 |
Ejemplares similares
-
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020) -
Bufalin Induces the Interplay between Apoptosis and Autophagy in Glioma Cells through Endoplasmic Reticulum Stress
por: Shen, Shuying, et al.
Publicado: (2014) -
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017) -
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins
por: Wang, Haiyong, et al.
Publicado: (2018) -
Blocking autophagy enhances the pro-apoptotic effect of bufalin on human gastric cancer cells through endoplasmic reticulum stress
por: Zhao, Hongyan, et al.
Publicado: (2017)